| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activated neutrophils as effector cells for bispecific antibodies
|
Valerius, T.
|
|
1997
|
45 |
3-4 |
p. 142-145
|
artikel
|
| 2 |
Approaches to implement bispecific antibody treatment of ovarian carcinoma
|
Canevari, S.
|
|
1997
|
45 |
3-4 |
p. 187-189
|
artikel
|
| 3 |
Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1
|
Kroesen, B. J.
|
|
1997
|
45 |
3-4 |
p. 203-206
|
artikel
|
| 4 |
Bispecific-Ab-based immunoassay of thyroid-stimulating hormone
|
Inouye, Kuniyo
|
|
1997
|
45 |
3-4 |
p. 159-161
|
artikel
|
| 5 |
Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome
|
Honeychurch, Jamie
|
|
1997
|
45 |
3-4 |
p. 171-173
|
artikel
|
| 6 |
Bispecific antibody treatment of murine B cell lymphoma
|
De Jonge, J.
|
|
1997
|
45 |
3-4 |
p. 162-165
|
artikel
|
| 7 |
CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma
|
Manzke , Oliver
|
|
1997
|
45 |
3-4 |
p. 198-202
|
artikel
|
| 8 |
Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor
|
Taylor, R. P.
|
|
1997
|
45 |
3-4 |
p. 152-155
|
artikel
|
| 9 |
Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer
|
van Ojik , H. H.
|
|
1997
|
45 |
3-4 |
p. 207-209
|
artikel
|
| 10 |
Clinical experience with CD64-directed immunotherapy. An overview
|
Curnow, Randall T.
|
|
1997
|
45 |
3-4 |
p. 210-215
|
artikel
|
| 11 |
Clinical perspectives of bispecific antibodies in cancer
|
de Gast, G. C.
|
|
1997
|
45 |
3-4 |
p. 121-123
|
artikel
|
| 12 |
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
|
Kufer, P.
|
|
1997
|
45 |
3-4 |
p. 193-197
|
artikel
|
| 13 |
Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein
|
Gerstmayer, Bernhard
|
|
1997
|
45 |
3-4 |
p. 156-158
|
artikel
|
| 14 |
Diabodies: small bispecific antibody fragments
|
Holliger, P.
|
|
1997
|
45 |
3-4 |
p. 128-130
|
artikel
|
| 15 |
FcγRI blockade and modulation for immunotherapy
|
Wallace, P. K.
|
|
1997
|
45 |
3-4 |
p. 137-141
|
artikel
|
| 16 |
Increased potency of Fc-receptor-targeted antigens
|
Guyre, P. M.
|
|
1997
|
45 |
3-4 |
p. 146-148
|
artikel
|
| 17 |
Lysis of murine B lymphoma cells by transgenic phagocytes via a human FcγRI×murine MHC class II bispecific antibody
|
Heijnen, Ingmar A. F. M.
|
|
1997
|
45 |
3-4 |
p. 166-170
|
artikel
|
| 18 |
Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins
|
Weiner, Louis M.
|
|
1997
|
45 |
3-4 |
p. 190-192
|
artikel
|
| 19 |
Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation
|
Wickham, T. J.
|
|
1997
|
45 |
3-4 |
p. 149-151
|
artikel
|
| 20 |
Targeting tumor cell destruction with CD64-directed bispecific fusion proteins
|
Graziano, Robert F.
|
|
1997
|
45 |
3-4 |
p. 124-127
|
artikel
|
| 21 |
T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: An effective in vivo antitumor strategy
|
Porter , Lewis E.
|
|
1997
|
45 |
3-4 |
p. 180-183
|
artikel
|
| 22 |
T-cell activation induced by anti-CD3 × anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand
|
Wooldridge, James E.
|
|
1997
|
45 |
3-4 |
p. 174-179
|
artikel
|
| 23 |
Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody
|
Renner, Cristoph
|
|
1997
|
45 |
3-4 |
p. 184-186
|
artikel
|
| 24 |
Tumor-specific T-bodies: towards clinical application
|
Eshhar, Zelig
|
|
1997
|
45 |
3-4 |
p. 131-136
|
artikel
|
Tijdschrift beschrijving